Regeneron Executive and Leadership Team

Leonard Schleifer, the Board co-Chair, President & Chief Executive Officer at Regeneron, directs the overarching strategy and operational execution for the biotechnology firm. Schleifer guides the company's mission to discover, develop, and commercialize innovative medicines for serious diseases, focusing on advanced science and proprietary technologies. This leadership role involves setting the strategic vision for creating life-changing treatments across oncology, eye diseases, inflammatory disorders, and rare diseases. By ensuring alignment across research, development, and commercialization efforts, Schleifer drives Regeneron's commitment to addressing significant unmet medical needs. The Chief Executive Officer's responsibilities include fostering a culture of scientific excellence and ensuring the company's long-term growth and market impact. Leonard Schleifer's executive oversight ensures the company remains at the forefront of medical innovation, translating complex scientific breakthroughs into tangible patient benefits.

Leonard Schleifer, the Co-Chair, President & Chief Executive Officer at Regeneron, spearheads the company's strategic direction and corporate governance. Schleifer's executive mandate encompasses guiding the discovery, development, and commercialization of novel therapies for severe illnesses, utilizing cutting-edge science and unique technologies. This critical position involves shaping the company's approach to tackling complex health challenges, including cancer, eye conditions, inflammatory diseases, and rare genetic disorders. The Chief Executive Officer's leadership ensures that Regeneron's pipeline of potential treatments progresses efficiently from research to market. By championing scientific rigor and innovation, Leonard Schleifer reinforces the company's dedication to improving patient outcomes worldwide. This executive function is central to Regeneron's mission of transforming scientific insights into impactful medical solutions.

Robert Landry, the Chief Financial Officer & Senior VP, Finance at Regeneron, manages the company's financial operations and fiscal strategy. Landry oversees all aspects of financial planning, accounting, treasury, and investor relations, ensuring the fiscal health and sustainability of the biotechnology firm. This executive role is pivotal in supporting Regeneron's mission to discover, develop, and commercialize innovative medicines by allocating resources effectively to research, development, and market expansion initiatives. The Chief Financial Officer's responsibilities include driving financial performance, managing capital, and providing strategic financial guidance to the leadership team. By maintaining strong financial discipline and transparency, Robert Landry enables Regeneron to continue its pursuit of life-changing treatments for serious diseases and maintain its position as a leader in the pharmaceutical industry.

Peter Weber, the Chief Marketing Officer at Regeneron, directs the strategic positioning and market engagement for the company's innovative medicines. Weber oversees the development and execution of comprehensive marketing strategies designed to communicate the value of Regeneron's life-changing treatments for serious diseases. This role involves understanding market dynamics and patient needs to effectively reach healthcare professionals and patient communities. The Chief Marketing Officer's responsibilities include leading cross-functional teams to ensure cohesive brand messaging and successful product launches. By translating scientific advancements into compelling market narratives, Weber supports Regeneron's mission to bring novel therapies to those in need. This executive function is crucial for maximizing the reach and impact of Regeneron's therapeutic portfolio.

Stephanie Moult, the Chief Marketing Officer & Chief Medical Officer at Regeneron, bridges critical commercial and clinical functions. Moult directs marketing initiatives while simultaneously overseeing medical affairs and clinical strategy for the company's therapeutic pipeline. This dual role ensures that Regeneron's innovative medicines are not only effectively marketed but also grounded in robust clinical evidence and patient-centric medical insights. The Chief Marketing Officer & Chief Medical Officer's responsibilities include aligning commercial strategies with clinical development goals, ensuring that Regeneron's treatments for serious diseases meet both market demands and rigorous medical standards. By integrating these vital perspectives, Moult drives the successful translation of scientific discovery into accessible, life-changing therapies for patients worldwide.

Corri Paulo, the Chief Of Staff To Senior Vice President Translational Sciences and Oncology at Regeneron, provides critical operational and strategic support within key scientific divisions. Paulo facilitates the seamless execution of initiatives related to translational sciences and oncology research, ensuring alignment with Regeneron's broader goals of developing innovative medicines. This role involves managing complex projects, coordinating cross-functional communication, and optimizing workflows to accelerate the advancement of novel therapies for serious diseases. The Chief Of Staff's responsibilities include enhancing the efficiency of the Senior Vice President's operations, thereby supporting Regeneron's commitment to scientific excellence and the creation of life-changing treatments. Corri Paulo's contributions are integral to driving progress in critical therapeutic areas.

Erick Honores, the Director, Global Procurement & Chief Marketing Officer, Advanced Therapies at Regeneron, holds a dual executive responsibility. Honores directs global procurement strategies, ensuring the efficient and cost-effective acquisition of resources essential for Regeneron's operations, while also leading marketing efforts for advanced therapies. This combined role ensures that the company's supply chain is robust and that its cutting-edge treatments are effectively positioned in the market. The Chief Marketing Officer, Advanced Therapies aspect of the role focuses on communicating the value and impact of Regeneron's most innovative medical solutions for serious diseases. Erick Honores' leadership drives both operational excellence and strategic market penetration for the company's advanced therapeutic programs.

Garvin Hyatt, the Chief of Staff Regeneron, provides essential strategic and operational support across the organization. Hyatt works closely with senior leadership to drive key initiatives and ensure the effective implementation of company-wide strategies. This role involves coordinating complex projects, facilitating communication between departments, and optimizing operational efficiency to support Regeneron's mission of discovering and developing life-changing medicines. The Chief of Staff's responsibilities are crucial for maintaining momentum in the company's pursuit of treatments for serious diseases, including cancer, eye diseases, and rare disorders. Garvin Hyatt's executive function is vital for enhancing organizational effectiveness and advancing Regeneron's scientific and commercial objectives.

Wrechelle Nantes, the Executive Assistant To the Chief Human Resources Officer at Regeneron, provides comprehensive administrative and operational support. Nantes manages critical functions that enable the Chief Human Resources Officer to effectively lead talent acquisition, employee development, and organizational culture initiatives. This role is instrumental in ensuring the smooth operation of the human resources department, which is vital for supporting Regeneron's scientific workforce and its mission to develop innovative medicines. The Executive Assistant's responsibilities include coordinating schedules, managing communications, and facilitating key HR processes that underpin the company's commitment to its employees and its pursuit of life-changing treatments for serious diseases.